Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 20% aftermarket. The company said the ...
15h
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS ...
Amazon Music and WPP unveiled Louder Than Cancer, an effort uniting top global artists to harness the power of music in recognition of World Cancer Day with creative leadership from WPP’s Grey Health, ...
The U.S. Food and Drug Administration (FDA) has approved Onapgo (apomorphine hydrochloride) injection, the first and only ...
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of ...
It is fourth time lucky for Supernus Pharmaceuticals, as its Parkinson’s specialist finally receives US approval for Onapgo ...
On April 4 (local time), the U.S. Food and Drug Administration (FDA) approved Onapgo, a treatment device for motor symptoms developed by Supernus Pharmaceuticals. This follows the approval of ...
The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...
The US Food and Drug Administration (FDA) has approved Supernus Pharmaceuticals’ Onapgo (apomorphine hydrochloride) injection to treat motor fluctuations in adults with advanced Parkinson’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback